JP2021502416A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502416A5
JP2021502416A5 JP2020544565A JP2020544565A JP2021502416A5 JP 2021502416 A5 JP2021502416 A5 JP 2021502416A5 JP 2020544565 A JP2020544565 A JP 2020544565A JP 2020544565 A JP2020544565 A JP 2020544565A JP 2021502416 A5 JP2021502416 A5 JP 2021502416A5
Authority
JP
Japan
Prior art keywords
seq
patient
cells
cancer
chain sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544565A
Other languages
English (en)
Japanese (ja)
Other versions
JP7437307B2 (ja
JP2021502416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/059039 external-priority patent/WO2019090134A1/en
Publication of JP2021502416A publication Critical patent/JP2021502416A/ja
Publication of JP2021502416A5 publication Critical patent/JP2021502416A5/ja
Priority to JP2023181486A priority Critical patent/JP7712338B2/ja
Application granted granted Critical
Publication of JP7437307B2 publication Critical patent/JP7437307B2/ja
Priority to JP2025115696A priority patent/JP2025148435A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544565A 2017-11-03 2018-11-02 ヒトがんの治療のためのモノクローナル抗体neo-201 Active JP7437307B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023181486A JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体neo-201
JP2025115696A JP2025148435A (ja) 2017-11-03 2025-07-09 ヒトがんの治療のためのモノクローナル抗体neo-201

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581380P 2017-11-03 2017-11-03
US62/581,380 2017-11-03
US201762592778P 2017-11-30 2017-11-30
US62/592,778 2017-11-30
PCT/US2018/059039 WO2019090134A1 (en) 2017-11-03 2018-11-02 Monoclonal antibody neo-201 for the treatment of human carcinomas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023181486A Division JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体neo-201

Publications (3)

Publication Number Publication Date
JP2021502416A JP2021502416A (ja) 2021-01-28
JP2021502416A5 true JP2021502416A5 (cg-RX-API-DMAC7.html) 2021-12-02
JP7437307B2 JP7437307B2 (ja) 2024-02-22

Family

ID=66332711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544565A Active JP7437307B2 (ja) 2017-11-03 2018-11-02 ヒトがんの治療のためのモノクローナル抗体neo-201
JP2023181486A Active JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体neo-201
JP2025115696A Pending JP2025148435A (ja) 2017-11-03 2025-07-09 ヒトがんの治療のためのモノクローナル抗体neo-201

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023181486A Active JP7712338B2 (ja) 2017-11-03 2023-10-20 ヒトがんの治療のためのモノクローナル抗体neo-201
JP2025115696A Pending JP2025148435A (ja) 2017-11-03 2025-07-09 ヒトがんの治療のためのモノクローナル抗体neo-201

Country Status (6)

Country Link
US (2) US11767367B2 (cg-RX-API-DMAC7.html)
EP (1) EP3735423A4 (cg-RX-API-DMAC7.html)
JP (3) JP7437307B2 (cg-RX-API-DMAC7.html)
CN (3) CN120860200A (cg-RX-API-DMAC7.html)
AU (2) AU2018360045B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019090134A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7555270B2 (ja) * 2018-02-13 2024-09-24 プレシジョン バイオロジックス、インコーポレイテッド Treg細胞を標的とするための方法及び組成物
MX2023013637A (es) * 2021-05-19 2024-02-13 Prec Biologics Inc Metodos y composiciones para tratar neoplasias hematicas.
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN115819596B (zh) * 2021-09-17 2026-06-02 优迈生物科技(连云港)有限公司 一种靶向人ceacam5/6的抗体、制备方法和应用
WO2023198019A1 (zh) * 2022-04-12 2023-10-19 盛禾(中国)生物制药有限公司 一种抗ceacam5和ceacam6抗体及其应用
CN116699135B (zh) * 2022-04-29 2025-11-07 中国医学科学院肿瘤医院 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用
EP4499710A4 (en) * 2022-05-19 2026-04-15 Prec Biologics Inc METHODS FOR ABLATION OF SUPPRESSIVE MYELOID CELLS USING A NEO-201 ANTIBODY
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Bcl-xl降解劑抗體結合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
EP3336104A1 (en) * 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US11020467B2 (en) * 2017-05-26 2021-06-01 Etubics Corporation Combination immunotherapies comprising IL-15 superagonists

Similar Documents

Publication Publication Date Title
Wang et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy
Sun et al. CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies
Darragh et al. Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
Joshi et al. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system
Seyedin et al. Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models
Herrera et al. Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Fournier et al. Trial watch: adoptively transferred cells for anticancer immunotherapy
Bhalla et al. Combining immunotherapy and radiotherapy in lung cancer
ES2754557T3 (es) Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia
RU2689160C2 (ru) Противораковая таргетная иммунотерапия с применением il-12
JP2017536812A (ja) バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞
KR20200029543A (ko) 암 면역요법을 위해 면역 조절제와 조합된 수용체 서브타입 및 기능 선택적 레티노이드 및 렉시노이드 화합물
He et al. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors
US20220111069A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
CA3128202A1 (en) Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
JP2018516881A (ja) 癌治療のためのnk細胞および抗体
Doloff et al. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
Wang et al. Combination of cytokine-induced killer cells and programmed cell death-1 blockade works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and non-small cell lung cancer
Wieder et al. Immunotherapy of melanoma: efficacy and mode of action
Guo et al. Tumor reductive therapies and antitumor immunity
JP2024514149A (ja) uPARを標的とするCAR-T細胞及びその使用
JP2020500161A5 (cg-RX-API-DMAC7.html)
Liu et al. Prospects and applications of NK therapy in the treatment of gliomas
Chen et al. Immunotherapy of Cancer by Targeting Regulatory T cells